TORONTO, Nov. 10, 2025 — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) has announced a non-brokered private placement offering of 480,769 common shares priced at $1.04 per share, aiming to raise gross proceeds of $500,000 CAD.
The offering is scheduled to close on November 12, 2025, pending regulatory approvals, including those from the TSX Venture Exchange, and standard closing conditions.
Arch Biopartners will allocate the proceeds as general working capital and to cover certain operating expenses not included in the company’s human trial funding grants.
The share issuance to a company officer qualifies as a “related party” transaction under Multilateral Instrument 61-101, but is exempt from valuation and minority shareholder approval requirements because the distributed Common Shares’ fair market value and the received consideration do not exceed 25% of Arch Biopartners’ market capitalization.
All common shares issued in the offering will be subject to a four-month hold period from the closing date. No finders’ fees will be paid in connection with the offering.
Arch Biopartners is a therapeutic biotech company focused on developing drugs for acute and chronic kidney diseases.
The company’s pipeline includes:
LSALT peptide: A Phase II trial targeting cardiac surgery-associated AKI.
Cilastatin: A repurposed drug in Phase II trial for toxin-induced AKI.
CKD Therapeutics: A pre-clinical program targeting chronic kidney disease.
These treatments address unmet needs in kidney care, targeting common causes of kidney damage and affecting millions globally.
Arch Biopartners currently has 66,356,366 common shares outstanding.
Aaron Benson, Director of Communications for Arch Biopartners, can be contacted at 647-428-7031.
For additional details on the company’s science and clinical trials, visit www.archbiopartners.com/our-science. The company can also be followed on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news.
Forward-looking statements in this release involve expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio.
These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management discussion and analysis under the heading “Business Risks and Uncertainties”.
Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contact:
Aaron Benson
Director of Communications
Arch Biopartners, Inc.
647-428-7031
Source: Arch Biopartners Inc.
